ArticleHepatology international2014
Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis.
Article in Hepatology international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04391348 (Prospective Study Evaluating the Combination of Positron Emission Tomography), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Study Evaluating the Combination of Positron Emission Tomography (PET) With 18F-FDG and 18 F-Fluorocholine for Optimization of Staging and Treatment Modification in Patients With Hepatocellular Carcinoma
Who cites it
30 citing papers in PubMed, 59 citations in OpenAlex.
- Prognostic Value ofCancers · 2026Article
- The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
- Dynamic, multiphase magnetic resonance imaging of in vivo physiological processes with long-lived hyperpolarizedScience advances · 2025Article
- Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).Liver cancer · 2023Article
- Bilateral Ovarian Metastases of Hepatocellular Carcinoma Diagnosed withNuclear medicine and molecular imaging · 2023Article
- Two Birds with One Stone: Hepatocellular Carcinoma and Small Cell Lung Cancer Imaged with [Diagnostics (Basel, Switzerland) · 2023Article
- Primary Peritoneal Hepatoid Adenocarcinoma Patients Treated by Complete Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).Indian journal of surgical oncology · 2023Article
- Review
- Emerging theragnostic radionuclide applications for hepatocellular carcinoma.Frontiers in nuclear medicine · 2023Review
- Influence of key histological characteristics on 18F-fluorodeoxyglucose /18F-choline positron emission tomography positivity in hepatocellular carcinoma: A machine learning study.Frontiers in medicine · 2023Article
- PET/CT withBiomedicines · 2022Article
- Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists.Radiographics : a review publication of the Radiological Society of North America, Inc · 2022Article
- 18F-FDG /18F-Choline Dual-Tracer PET Behavior and Tumor Differentiation in HepatoCellular Carcinoma. A Systematic Review.Frontiers in medicine · 2022Review
- Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism.Cancers · 2021Review
- [European journal of nuclear medicine and molecular imaging · 2021Article
- Prognostic Value of Metabolic Imaging Data ofCancers · 2021Article
- Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).Liver cancer · 2020Article
- Predicting tumor recurrence using metabolic indices ofOncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of fluorine-18-fluorodeoxygluose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in hepatocellular carcinoma (HCC) has not been firmly established yet and its sensitivity has been reported to be in the range of 40-60 %. Because of this relatively low sensitivity alternative tracers have been proposed. The aim of our review is to analyse the literature data on the diagnostic role of (18)F/(11)C-choline PET/CT in the evaluation of HCC. A comprehensive computer literature search of PubMed/MEDLINE, Embase and Scopus databases was conducted to find relevant published articles about the role of whole-body (18)F-choline or (11)C-choline PET or PET/CT in patients with HCC. Furthermore, a meta-analysis about the detection rate of this method in HCC was performed. Six articles were included in this systematic review and discussed. The meta-analysis of five out of six articles showed a DR of 84 % (95 % CI 79-89 %). The DR increased when poorly differentiated HCC was excluded from the analysis. Radiolabelled choline PET or PET/CT could be a valuable tool in detecting HCC and it is better than (18)F-FDG PET/CT, especially in well to moderately differentiated lesions; on the other hand, poorly differentiated and higher-stage HCC could be better evaluated with (18)F-FDG and dual tracer imaging should be considered and could be potentially useful to increase accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.